CASAD for Severe Diarrhea in the Emergency Department
A Double-Blinded Placebo-Controlled Pilot Trial of Calcium Alumina-Silicate (CASAD) in the Treatment of Severe Diarrhea (Grade 3 or 4) in Cancer Patients Presenting for Emergency Care
Sponsor: M.D. Anderson Cancer Center
Terminated
Slow Accrual
A NA clinical study on Cancer and Diarrhea, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Jan 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 4 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Terminated NA
-
Jun 2018 — Aug 2018 [monthly]
Terminated NA
-
Feb 2017 — Jun 2018 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- Salient Pharmaceuticals Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .